Joseph Walter Vazzano Abeona Therapeutics Inc. (ABEO) insider trading activity

Joseph Walter Vazzano is Chief Financial Officer of ABEONA THERAPEUTICS INC.. Currently has a direct ownership of 453,631 shares of ABEO, which is worth approximately $2.02 Million. The most recent transaction as insider was on Sep 29, 2025, when has been sold 9,035 shares (Common Stock) at a price of $5.39 per share, resulting in proceeds of $48,698. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 454K

1.95% 3M change

24.21% 12M change

Total Value Held $2.02 Million

Joseph Walter Vazzano Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 29 2025	SELL Open market or private sale	$48,698 $5.39 p/Share	9,035 Reduced 1.95%	453,631 Common Stock
Aug 15 2025	SELL Open market or private sale	$110,400 $7.36 p/Share	15,000 Reduced 3.14%	462,666 Common Stock
Jul 22 2025	SELL Open market or private sale	$9,973 $6.64 p/Share	1,502 Reduced 0.31%	477,666 Common Stock
Jul 09 2025	SELL Open market or private sale	$148,908 $5.86 p/Share	25,411 Reduced 5.04%	479,168 Common Stock
Jun 06 2025	SELL Open market or private sale	$120,294 $6.76 p/Share	17,795 Reduced 3.5%	491,246 Common Stock
Jun 05 2025	BUY Grant, award, or other acquisition	-	13,333 Added 2.57%	504,579 Common Stock
Mar 14 2025	SELL Payment of exercise price or tax liability	$3,623 $5.29 p/Share	685 Reduced 0.13%	509,041 Common Stock

Jan 21 2025	BUY Grant, award, or other acquisition	-	144,509 Added 22.09%	509,726 Common Stock
Sep 28 2024	SELL Payment of exercise price or tax liability	$37,625 $5.89 p/Share	6,388 Reduced 1.72%	365,217 Common Stock
Jul 21 2024	SELL Payment of exercise price or tax liability	$5,391 $5.11 p/Share	1,055 Reduced 0.28%	371,605 Common Stock
Jul 08 2024	BUY Grant, award, or other acquisition	-	155,200 Added 29.4%	372,660 Common Stock
Jun 05 2024	SELL Payment of exercise price or tax liability	$74,164 $4.52 p/Share	16,408 Reduced 7.02%	217,460 Common Stock
Apr 25 2024	BUY Open market or private purchase	$17,609 $3.14 p/Share	5,608 Added 2.34%	233,868 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$5,722 $8.14 p/Share	703 Reduced 0.31%	228,260 Common Stock
Sep 29 2023	SELL Payment of exercise price or tax liability	$24,483 $3.93 p/Share	6,230 Reduced 2.65%	228,963 Common Stock
Sep 19 2023	BUY Open market or private purchase	$11,280 $3.76 p/Share	3,000 Added 1.24%	238,179 Common Stock
Jul 24 2023	SELL Payment of exercise price or tax liability	$4,427 $3.73 p/Share	1,187 Reduced 0.5%	235,179 Common Stock
Jun 05 2023	BUY Grant, award, or other acquisition	-	141,908 Added 37.51%	236,366 Common Stock
Mar 15 2023	SELL Payment of exercise price or tax liability	$2,059 $2.6 p/Share	792 Reduced 0.83%	94,458 Common Stock
Nov 18 2022	BUY Open market or private purchase	$10,000 $4.0 p/Share	2,500 Added 2.56%	95,250 Common Stock
Sep 28 2022	BUY Grant, award, or other acquisition	-	72,750 Added 43.96%	92,750 Common Stock
Jul 21 2022	BUY Grant, award, or other acquisition	-	12,000 Added 37.5%	20,000 Common Stock
Mar 14 2022	BUY Grant, award, or other acquisition	-	200,000 Added 50.0%	200,000 Common Stock

Also insider at

ATXI

AVENUE THERAPEUTICS, INC. Healthcare

Chief Financial Officer

ALLR

Allarity Therapeutics, Inc. Healthcare

Director

JWV